Interestingly, AnxA1 ablation restores the sensitivity of colorectal and pancreatic cancers to chemotherapeutic agents through the inhibition of the drug efflux pump, p-glycoprotein [64,65]. The gene discussed is ANXA1; the disease is pancreatic neoplasm.